Skip to main content
SpringerLink
Log in

Significance of OCT1 Expression in Acute Myeloid Leukemia

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Organic cation transporter 1 (OCT1) is one of the membrane proteins in the large solute carrier (SLC) family. It participates in the transport of organic cations, i.e. nutrients, neurotransmitters, metabolites or drugs in an electrogenic manner and translocate various cationic cytostatics. Knowledge concerning the expression of drug transporters in tumor cells may help to develop cytotoxic agents that are targeted to specific tumors. OCT1 expression and its relationship to the proliferation of cancer cells, development of metastases and resistance to chemotherapy has been observed in solid tumors. There is no data concerning the significance of OCT1 expression in the clinical course and treatment results in acute myeloid leukemia (AML). The objective of the study was firstly to evaluate OCT1 mRNA expression in patients with newly diagnosed de novo AML, and secondly to compare the obtained results to the healthy control group as well as analyze them according to leukemia subtypes, CD34 expression, cytogenetic and molecular factors and treatment results. 101 patients with AML, excluding the subtype classified as M3 by French-American-British (FAB) criteria, were analyzed. The control group consisted of 26 healthy individuals. The evaluated material was bone marrow (BM). Real-time quantitative polymerase chain reaction (RQ-PCR) was used in the study as a method of evaluating OCT1 mRNA expression. The study showed a statistically significant lower expression of OCT1 mRNA in patients with AML in comparison to the control group. The level of OCT1 mRNA expression was lowest for CD34+ leukemia. No significant correlation between OCT1 mRNA expression and cytogenetic and molecular factors was observed. A significant influence of OCT1 mRNA expression on the clinical outcome of the disease was observed: patients with lower expression had higher chances of achieving complete remission (CR) and longer overall survival (OS).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Christ O, Feuring-Buske M, Hiddemann W et al (2007) Pathobiology of acute myeloid leukemia. Med Clin 102:290–295

    CAS  Google Scholar 

  2. Redmond KM, Wilson TR, Johnston PG et al (2008) Resistance mechanisms to cancer chemotherapy. Front Biosci 13:5138–5154

    Article  CAS  PubMed  Google Scholar 

  3. Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 7:1227–1251

    Article  Google Scholar 

  4. Gründemann D, Gorboulev V, Gambaryan S et al (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549–552

    Article  PubMed  Google Scholar 

  5. Hayer-Zillgen M, Brüss M, Bönisch H (2002) Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2, and hOCT3. Br J Pharmacol 136:829–836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Engler JR, Zannettino AC, Bailey CG et al (2011) OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica 96:213–220

    Article  PubMed  Google Scholar 

  7. Komazawa H, Yamaguchi H, Hidaka K et al (2013) Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure. J Pharm Sci 3:1086–1094

    Article  Google Scholar 

  8. Nies AT, Koepsell H, Winter S et al (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 4:1227–1240

    Article  Google Scholar 

  9. Huang Y, Sadee W (2006) Membrane transporters and channels in chemoresistance and sensitivity of tumor cells. Cancer Lett 239:168–182

    Article  CAS  PubMed  Google Scholar 

  10. Zhang S, Lovejoy KS, Shima JE (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847–8857

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Arimany-Nardi C, Montraveta A, Lee-Vergés E et al (2015) Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. Pharmacogenomics J 4:363–371

    Article  Google Scholar 

  12. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830

    Article  CAS  PubMed  Google Scholar 

  13. O’Hare T, Corbin AS, Druker BJ (2006) Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 16:92–99

    Article  PubMed  Google Scholar 

  14. Apperley JF (2007) Mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 8:1018–1029

    Article  CAS  PubMed  Google Scholar 

  15. Wang L, Giannoudis A, Lane S et al (2008) Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258–264

    Article  CAS  PubMed  Google Scholar 

  16. Jonker JW, Schinkel AH (2004) Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2 and 3 (SLC22A1-3). J Pharmacol Exp Ther 308:2–9

    Article  CAS  PubMed  Google Scholar 

  17. Bennett JM, Catovsky D, Daniel MT et al (1985) Proposals for the classification of the acute leukemias. A report of the French-American-British (FAB) co-operative group. Ann Intern Med 103:620–625

    Article  CAS  PubMed  Google Scholar 

  18. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of Tumours of Haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, France

    Google Scholar 

  19. Döhner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European leukemia net. Blood 115:453–474

    Article  PubMed  Google Scholar 

  20. Fey MF, Greil R, Jost LM (2005) ESMO guidelines task force. ESMO minimum clinical recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. Ann Oncol 1:48–49

    Article  Google Scholar 

  21. Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yates J, Glidewell O, Wiernik P et al (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60:454–462

    CAS  PubMed  Google Scholar 

  23. Wrzesień-Kus A, Robak T, Jamroziak K et al (2002) The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of polish acute leukemia group (PALG) phase II study. Neoplasma 49:405–411

    PubMed  Google Scholar 

  24. Kabayashi D, Aizawa S, Maeda T et al (2004) Expression of organic cation transporter OCTN1 in hematopoietic cells during erythroid differentiation. Exp Hematol 32:1156–1162

    Article  Google Scholar 

  25. Karlic H, Lohninger A, Laschan C et al (2003) Downregulation of carnitine acyltransferases and organic cation transporter OCTN2 in mononuclear cells in healthy elderly and patients with myelodysplastic syndromes. J Mol Med 81:435–442

    Article  CAS  PubMed  Google Scholar 

  26. Bazeos A, Marin D, Gerrard G et al (2009) BCR-ABL1 oncogene downregulates the expression of OCT1 in CML. ASH Annu Meet Abstr 114:3248

    Google Scholar 

  27. Bazeos A, Marin D, Reid AG et al (2010) hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 24:1243–1245

    Article  CAS  PubMed  Google Scholar 

  28. Engler JR, Frede A, Saunders VA et al (2010) Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 24:765–770

    Article  CAS  PubMed  Google Scholar 

  29. Razga F, Racil Z, Polakova KM et al (2011) The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. Int J Hematol 94:303–306

    Article  PubMed  Google Scholar 

  30. White DL, Dang P, Engler J et al (2010) Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28:2761–2767

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland

    Ewa Stefanko, Justyna Rybka, Bożena Jaźwiec, Sylwia Stąpor, Kazimierz Kuliczkowski & Tomasz Wróbel

  2. Department of Clinical Genetics, Collegium Medicum Nicolaus Copernicus University, Bydgoszcz, Poland

    Olga Haus

Authors
  1. Ewa Stefanko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Justyna Rybka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bożena Jaźwiec
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olga Haus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sylwia Stąpor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazimierz Kuliczkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomasz Wróbel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ewa Stefanko.

Ethics declarations

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stefanko, E., Rybka, J., Jaźwiec, B. et al. Significance of OCT1 Expression in Acute Myeloid Leukemia. Pathol. Oncol. Res. 23, 665–671 (2017). https://doi.org/10.1007/s12253-016-0161-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-016-0161-7

Keywords

Search

Navigation